What Is Eicosapentaenoic Acid and What Does It Do?

Eicosapentaenoic acid, usually called EPA, is a long-chain omega-3 fat found mainly in oily fish, shellfish, and the marine microalgae that produce it in the first place. It does a lot of different things in the body, but the core story is about inflammation: EPA competes with a pro-inflammatory fat already in your cell membranes, dials down the signals that drive swelling and tissue damage, and generates its own class of molecules that actively help inflammation resolve. That anti-inflammatory action ripples outward into heart health, brain function, joint comfort, and liver metabolism, and a purified form of EPA became the first fish-oil product the FDA approved specifically to reduce cardiovascular risk.

Where EPA Comes From

Your body cannot build EPA from scratch. The raw material is alpha-linolenic acid (ALA), a shorter omega-3 fat found in flaxseed, walnuts, and canola oil. In theory, your liver can lengthen and desaturate ALA into EPA, but in practice the conversion rate is low. Tracer studies using radioisotope-labeled ALA estimated conversion to EPA at roughly 6% when the background diet was high in saturated fat.¹ A controlled feeding trial found the conversion percentage could shift depending on how much ALA and linoleic acid (an omega-6 fat) people ate: lowering linoleic acid intake nudged conversion upward, while flooding the diet with extra ALA actually decreased the fraction that made it to EPA.² Either way, most nutrition researchers treat ALA as an unreliable route to meaningful EPA levels and point people toward preformed EPA from marine sources instead.

The richest food sources are fatty cold-water fish: salmon, mackerel, sardines, herring, and anchovies. The fish themselves do not synthesize EPA. They accumulate it by eating smaller organisms that ate microalgae, the true primary producers of both EPA and DHA in the ocean.³ That ecological origin matters for sustainability, and it has opened the door to algae-derived supplements that skip the fish entirely.⁴ Researchers have also demonstrated that transferring genes from marine microalgae into oilseed crops can produce omega-3 long-chain fats on land, though commercial-scale production is still evolving.⁵

How EPA Tamps Down Inflammation

The central mechanism behind most of EPA’s benefits is its rivalry with arachidonic acid (AA), an omega-6 fat that sits in cell membranes throughout the body. When cells are damaged or stressed, enzymes called cyclooxygenase and lipoxygenase clip AA out of the membrane and convert it into signaling molecules that ramp up inflammation, pain, and swelling. EPA competes with AA for those same enzymes, and the products it generates are far less inflammatory.⁶ Over time, eating more EPA shifts the balance in your membranes: the ratio of EPA to AA rises, so there is simply less raw material available for the most aggressive inflammatory signals.⁷

EPA also plays a role on the back end of inflammation, not just turning it down but helping it switch off entirely. Your body converts EPA into a family of specialized molecules called E-series resolvins. These resolvins actively promote the resolution phase of inflammation: they signal immune cells to stop flooding into tissues and start cleaning up debris.⁸ One member of this family, resolvin E2, was shown in animal models to potently block the infiltration of immune cells during an inflammatory challenge.⁹ So EPA is not just an anti-inflammatory agent in the passive sense of producing weaker signals; it generates molecules whose entire purpose is to tell your immune system that the job is done.

EPA and Heart Health

Cardiovascular disease is where EPA has been studied the most intensively, and the evidence base is substantial. The chain from mechanism to clinical outcome runs through several links: triglyceride lowering, plaque stabilization, and a large randomized trial showing fewer heart attacks and strokes.

High blood triglycerides are a well-established risk factor for heart disease, and both EPA and DHA are effective at bringing them down. The main way they do this is by reducing the liver’s production of triglyceride-rich particles called VLDL. Rather than causing fat to build up in the liver, EPA appears to promote the burning of fatty acids for energy, so less fat gets packaged and shipped into the bloodstream.¹⁰ Laboratory work in liver cells confirmed the effect: when exposed to EPA, the cells channeled fats into membrane-building phospholipids rather than into the triglycerides that get exported as VLDL.¹¹ One advantage EPA holds over DHA in this context is that it lowers triglycerides without raising LDL cholesterol.¹²

Beyond the lipid numbers, EPA appears to physically embed itself in arterial plaques. Human plaques readily incorporate EPA, and research suggests this may make the plaques less likely to rupture and trigger a heart attack or stroke.¹³ Clinical studies in patients on statin therapy have found that EPA may decrease plaque vulnerability and slow plaque progression.¹⁴

The REDUCE-IT Trial

The biggest splash EPA has made in cardiology came from a trial called REDUCE-IT, published in the New England Journal of Medicine. The trial enrolled over 8,000 patients who were already on statin therapy but still had elevated triglycerides and high cardiovascular risk. Half received 4 grams per day of icosapent ethyl, a highly purified EPA product, and half received a placebo. Over about five years of follow-up, the EPA group had about a quarter fewer major cardiovascular events: a primary endpoint event occurred in roughly 17% of the EPA group compared with 22% of the placebo group. Cardiovascular death was also lower in the EPA group.¹⁵ On the strength of these results, icosapent ethyl became the first fish-oil-derived product the FDA approved to reduce atherosclerotic cardiovascular risk.¹⁶

The trial is not without controversy. Critics have pointed to the choice of placebo (mineral oil), which may have slightly worsened outcomes in the control group by interfering with statin absorption. Debate continues over how much of the benefit comes from triglyceride lowering versus EPA’s other effects on inflammation and plaque stability. Still, the size and rigor of the trial, and the consistency of the benefit across multiple endpoints, have made purified EPA a fixture in cardiovascular risk management guidelines.

Depression and Mental Health

One of the more striking findings about EPA is that it seems to matter for mood in a way that its cousin DHA does not. Two separate meta-analyses of randomized controlled trials have converged on the same conclusion: supplements that are predominantly EPA reduce symptoms of depression, while supplements that are predominantly DHA do not. One analysis found that formulations with at least 60% EPA at doses up to 1 gram per day produced a meaningful improvement in depression scores, whereas DHA-dominant formulations showed no significant benefit.¹⁷ An earlier meta-analysis found the same pattern: supplements with more than half EPA significantly reduced depressive symptoms, while pure DHA supplements had essentially zero effect.¹⁸

A later updated meta-analysis confirmed the split, with EPA-pure and EPA-major treatments showing benefit while DHA-focused treatments did not.¹⁹ The effect sizes are modest. Nobody is suggesting EPA replaces antidepressant medication. But the consistency across analyses is hard to dismiss, and it points to something genuinely different about what EPA does in the brain compared with DHA.

Part of the explanation may involve neuroinflammation. In laboratory and animal studies, EPA administration dampened the production of pro-inflammatory signaling molecules in brain immune cells and promoted anti-inflammatory ones. In rats, an EPA-enriched diet given before an inflammatory challenge protected the hippocampus from losing its anti-inflammatory defenses.²⁰ Depression is increasingly understood to involve low-grade brain inflammation in at least some patients, so EPA’s ability to calm neuroinflammation could explain why it outperforms DHA in mood trials.

Joint Health and Rheumatoid Arthritis

Given that EPA’s headline act is dampening inflammation, it makes sense that it would be studied in conditions defined by chronic joint inflammation. Clinical trials in rheumatoid arthritis have found that omega-3 supplementation (EPA and DHA together) can modestly reduce the number of swollen and tender joints and may influence overall disease activity.²¹ The effects are not dramatic enough to replace disease-modifying drugs, but some patients report meaningful improvements in morning stiffness and joint pain, and some trials have shown that omega-3 supplementation allows patients to reduce their use of anti-inflammatory medications. The mechanism is the same one driving EPA’s cardiovascular benefits: less arachidonic acid getting converted into the pro-inflammatory messengers that drive joint swelling.

Liver Fat and Metabolic Health

Non-alcoholic fatty liver disease (NAFLD) is one of the most common metabolic conditions worldwide, and omega-3 fats have shown promise in reducing the amount of fat stored in the liver. Reviews of clinical trials have concluded that diets supplemented with DHA alone, or with DHA and EPA together, are safe and effective at lowering liver fat, though the evidence is more mixed when it comes to whether they can also reduce liver inflammation and scarring in more advanced cases.²²

Animal research has dug into the mechanism, finding that EPA treatment reduced fat accumulation in the liver and calmed lobular inflammation. The protective effects appeared to work through multiple channels: suppressing the creation of new fat, ramping up the burning of existing fat, and remodeling the types of fats present in liver cell membranes.²³ This is still an active area of research, and we do not yet have large human trials isolating EPA’s specific contribution apart from DHA’s in the context of fatty liver.

How EPA Differs From DHA

EPA and DHA are often lumped together under the umbrella of “fish oil omega-3s,” and they do share many properties. But they are not interchangeable. EPA has 20 carbon atoms and 5 double bonds; DHA has 22 carbons and 6 double bonds. That small structural difference translates into meaningfully different behavior in cell membranes and different effects on certain health outcomes.

At the membrane level, the two fats sit in different positions and interact with neighboring molecules differently. X-ray diffraction studies have shown that EPA tends to extend across the oily interior of the membrane, while DHA positions itself more toward the outer surface near the head groups of neighboring fats.²⁴ When cholesterol is present in the membrane, the two fats also differ in how much they change membrane flexibility.²⁵ These structural differences help explain the divergent clinical findings: EPA is better suited for plaque stabilization and seems more active against depression, while DHA plays a larger structural role in brain and retinal tissue, where it concentrates heavily. Researchers have noted that EPA and DHA differ in their effects on lipid oxidation, inflammatory markers, and endothelial function.¹³

For someone choosing a supplement, the practical takeaway is that a product labeled “omega-3” or “fish oil” that delivers mostly DHA will not necessarily do what the EPA-focused research promises. The depression meta-analyses in particular make this clear: the benefit belongs to EPA-dominant formulations, not to omega-3 fats in general.

Supplement Forms and Bioavailability

Not all omega-3 supplements deliver EPA equally well. The chemical form the EPA arrives in affects how much actually makes it into your bloodstream. A head-to-head comparison of several formulations given at the same EPA+DHA dose found that re-esterified triglycerides were absorbed about 24% better than natural fish oil, while ethyl esters were absorbed about 27% less efficiently than natural fish oil. Free fatty acid forms fell in between, roughly comparable to natural triglycerides.²⁶

Krill oil, which delivers EPA and DHA partly bound to phospholipids, has also attracted attention. One bioavailability study found that krill oil produced the highest EPA+DHA incorporation into blood phospholipids over 72 hours, followed by re-esterified triglyceride fish oil, with ethyl ester fish oil trailing behind. However, the differences were not statistically significant for DHA or the combined total, mainly because individual variability was high.²⁷ As a practical matter, taking any omega-3 supplement with a meal that contains some fat improves absorption substantially, regardless of the formulation.

Safety Concerns Worth Knowing About

EPA is generally well tolerated, but high-dose purified EPA supplements are not entirely risk-free. Two issues come up repeatedly in the clinical literature: bleeding and atrial fibrillation.

On bleeding, a systematic review and meta-analysis of randomized trials found that high-dose purified EPA increased the relative risk of bleeding by about 50%, but the absolute increase was small, roughly 0.6%. The bleeding risk scaled with the EPA dose but was not made significantly worse by background use of antiplatelet drugs like aspirin.²⁸ The underlying biology makes sense: EPA reduces platelet aggregation through multiple pathways, including inhibiting the same clotting signals that platelets normally rely on.²⁹ Early research in the 1980s documented that a fish-rich diet high in EPA prolonged bleeding time by about 42% and reduced platelet stickiness in ways that persisted for weeks after the diet ended.³⁰ For most people this mild anti-clotting effect is part of the cardiovascular benefit, but if you are scheduled for surgery or are already on blood thinners, it is worth discussing with your doctor.

On atrial fibrillation, an updated meta-analysis of 35 trials covering over 114,000 people found that the risk was dose- and population-dependent. Only patients at high cardiovascular risk who took high doses of EPA/DHA (above 1,500 mg/day) showed a statistically significant increase in atrial fibrillation risk, with an absolute risk difference of about 0.8%. Patients at lower baseline risk, and those taking lower doses, did not have a meaningful increase.³¹ A secondary analysis of one trial in elderly heart-attack survivors found the same paradox: higher EPA levels in the blood were associated with fewer major cardiovascular events but a higher rate of atrial fibrillation.³² The clinical significance of this atrial fibrillation signal is still debated. In the REDUCE-IT trial, the net cardiovascular benefit of EPA far outweighed the excess atrial fibrillation cases, but for someone who already has a history of the arrhythmia, the risk-benefit calculation deserves a closer look.

Cancer Cachexia and Muscle Wasting

One area where early enthusiasm has not fully panned out is cancer-related muscle wasting, or cachexia. Initial smaller studies found that EPA supplementation improved lean body mass, appetite, and quality of life in patients with advanced cancer. The biological rationale was solid: cachexia involves systemic inflammation, and EPA’s anti-inflammatory properties seemed like a natural fit. However, subsequent larger phase III trials reported minimal benefits.³³ The current view is that EPA alone is unlikely to reverse cachexia once it is established, though it may play a supporting role as part of a multimodal approach that includes nutrition, exercise, and other interventions. The story is a useful reminder that having a plausible mechanism does not guarantee a large clinical effect, and that inflammation is not the only driver of every condition it touches.